- NeuroPace (NPCE, Financial) anticipates minimal tariff impact on its operations and financial results due to its US-based manufacturing and sales strategy.
- The company maintains its gross margin guidance for 2025, including for DIXI Medical SEEG products.
- NeuroPace will report Q1 2025 financial results on May 13, 2025, after market close.
NeuroPace, Inc. (NPCE) has announced that it expects minimal impact from recently implemented tariffs on its operations and financial outcomes. The company attributes this resilience to its strategic focus on manufacturing and sales predominantly within the United States, with limited exposure to international supply chains for its RNS System.
Reassuring investors, NeuroPace has reaffirmed its gross margin guidance for 2025, indicating confidence in maintaining its financial targets despite potential macroeconomic headwinds. The company stated that it expects no significant effect on the gross margin of DIXI Medical SEEG products, even as it proceeds with terminating its SEEG distribution agreement with DIXI Medical effective October 1, 2025, followed by a six-month wind-down period through the first quarter of 2026.
Looking ahead, NeuroPace remains committed to providing updates on its financial performance. The company is set to release its first quarter 2025 financial results on May 13, 2025, post-market close. This will be followed by a conference call at 1:30 p.m. Pacific Time, where management will discuss the company's performance and future prospects.
